Cinitapride tartrate
CAS: 96623-56-2
Ref. 3D-FC146198
| 1mg | Discontinued | ||
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued |
Product Information
Cinitapride is a prokinetic drug that is used to treat symptoms of gastroesophageal reflux disease and Parkinson's disease. It increases the speed with which food moves through the digestive tract by increasing the muscle contractions in the stomach, thereby decreasing the amount of time it takes for food to move through the intestines. Cinitapride also has been shown to increase levels of PGE2 in humans. In addition, cinitapride is a potent inhibitor of 5-HT2 receptors. The therapeutic effect of cinitapride may be due to its ability to inhibit hydrogen tartrate (HAT) production by recombinant cytochrome P450 enzymes. This inhibition leads to decreased levels of HAT substrate, which decreases HAT activity and inhibits platelet aggregation. Cinitapride also inhibits metoprolol succinate from binding with dinucleotide phosphate (DNP), resulting in an increased rate of reaction between DNP and oxygen molecules, leading to
